# Edwards Lifesciences Corp (EW)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/edwards-lifesciences-corp/ JSON: https://steadybase.io/company/edwards-lifesciences-corp.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Edwards Lifesciences Corp
- Ticker: EW (NYSE)
- SEC CIK: 0001099800
- Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Headquarters: Irvine, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: edwards.com
- LinkedIn: https://www.linkedin.com/company/edwards-lifesciences
- Next earnings date: Feb 15, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $6.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/0001099800-26-000009-index.html
- Operating income: $1.3B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/0001099800-26-000009-index.html
- Net income: $1.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/0001099800-26-000009-index.html
- SG&A: $2.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/0001099800-26-000009-index.html
- Employees: 16,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm
- Shares outstanding: 575,000,000 as of Oct 31, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000054/0001099800-26-000054-index.html
- Auditor: Pricewaterhousecoopers LLP, Irvine, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm

## Business

Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $6.1B | $1.3B | $1.1B | $2.1B |
| Dec 31, 2024 | $5.4B | $1.4B | $4.2B | $1.8B |
| Dec 31, 2023 | $5.0B | $1.3B | $1.4B | $1.6B |
| Dec 31, 2022 | $4.5B | $1.5B | $1.5B | $1.4B |
| Dec 31, 2021 | $5.2B | $1.7B | $1.5B | $1.5B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/edwards-lifesciences-corp.json

## Officers and directors

- Bernard Zovighian, CEO of Edwards Lifesciences. LinkedIn: https://linkedin.com/in/bernardzovighian. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000053/ex-991q32026.htm
- Bernard J. Zovighian, CEO. Source: Form 4 filed Jul 27, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826006743/0001225208-26-006743-index.htm
- Theodora Mistras, CVP, Chief Financial Officer. Source: Form 4 filed Jul 10, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826006578/0001225208-26-006578-index.htm
- Scott B. Ullem, CVP, Chief Financial Officer. Source: Form 4 filed May 11, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826005133/0001225208-26-005133-index.htm
- Andrew M. Dahl, SVP, Corporate Controller. Source: Form 4 filed Sep 14, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826007811/0001225208-26-007811-index.htm
- Wayne Markowitz, CVP, JAPAC. Source: Form 4 filed Sep 14, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826007812/0001225208-26-007812-index.htm
- Daniel J. Lippis, CVP, TAVR. Source: Form 4 filed Sep 11, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826007774/0001225208-26-007774-index.htm
- Daveen Chopra, CVP, TMTT, Surgical & IHFM. Source: Form 4 filed Sep 11, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826007775/0001225208-26-007775-index.htm
- Annette Bruls, CVP, EMEACLA. Source: Form 4 filed Aug 28, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000122520826007377/0001225208-26-007377-index.htm
- Annette Brüls, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Annette M. Brüls, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Daniel Lippis, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- David T. Feinberg, MD, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Kieran T. Gallahue, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Leslie C. Davis, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Leslie S. Heisz, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Nicholas J. Valeriani, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Paul A. LaViolette, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Ramona Sequeira, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Steven R. Loranger, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm
- Wayne T. Markowitz, Named in proxy. Source: DEF 14A filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000053/ew-20261104.htm
- Aug 28, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000048/ew-20260825.htm
- Jul 23, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ew-20260723.htm
- May 8, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000028/ew-20260507.htm
- May 4, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000023/ew-20260502.htm
- Apr 23, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/ew-20260423.htm
- Feb 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/ew-20260210.htm
- Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000002/ew-20260109.htm
- Oct 30, 2025: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000119312525258662/d50813d8k.htm
- Oct 30, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/ew-20251030.htm

## Insider trades (Form 4)

- Nov 9, 2026: Bernard J. Zovighian (CEO) sold 23,100 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826008780/0001225208-26-008780-index.htm
- Nov 9, 2026: Donald E. Bobo Jr (CVP,Strategy/Corp Development) sold 48,900 shares, about $5.0M. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826008779/0001225208-26-008779-index.htm
- Oct 8, 2026: Daniel J. Lippis (CVP, TAVR) sold 619 shares, about $53,017. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826008338/0001225208-26-008338-index.htm
- Sep 11, 2026: Daniel J. Lippis (CVP, TAVR) sold 619 shares, about $54,169. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826007774/0001225208-26-007774-index.htm
- Aug 31, 2026: Andrew M. Dahl (SVP, Corporate Controller) sold 544 shares, about $49,537. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826007408/0001225208-26-007408-index.htm
- Aug 28, 2026: Annette Bruls (CVP, EMEACLA) sold 2,644 shares, about $237,907. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826007377/0001225208-26-007377-index.htm
- Aug 26, 2026: Daveen Chopra (CVP, TMTT, Surgical & IHFM) sold 31,800 shares, about $2.9M. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826007335/0001225208-26-007335-index.htm
- Aug 26, 2026: Wayne Markowitz (CVP, JAPAC) sold 1,240 shares, about $113,423. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826007332/0001225208-26-007332-index.htm
- Aug 11, 2026: Daniel J. Lippis (CVP, TAVR) sold 619 shares, about $56,967. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826007065/0001225208-26-007065-index.htm
- Jul 30, 2026: Wayne Markowitz (CVP, JAPAC) sold 146.31 shares, about $12,587. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826006853/0001225208-26-006853-index.htm
- Jul 28, 2026: Wayne Markowitz (CVP, JAPAC) sold 9,628 shares, about $818,958. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826006777/0001225208-26-006777-index.htm
- Jul 27, 2026: Bernard J. Zovighian (CEO) sold 2,920.55 shares, about $245,122. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826006743/0001225208-26-006743-index.htm
- Jul 10, 2026: Daniel J. Lippis (CVP, TAVR) sold 619 shares, about $56,762. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826006576/0001225208-26-006576-index.htm
- Jun 30, 2026: Daniel J. Lippis (CVP, TAVR) sold 619 shares, about $56,577. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826006263/0001225208-26-006263-index.htm
- Jun 17, 2026: Bernard J. Zovighian (CEO) sold 523 shares, about $45,982. Source: https://www.sec.gov/Archives/edgar/data/1099800/000122520826006103/0001225208-26-006103-index.htm

## What management said

- "We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook" Bernard Zovighian, CEO of Edwards Lifesciences (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000053/ex-991q32026.htm

## Latest filings

- 8-K filed Aug 28, 2026: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000048/ew-20260825.htm
- 10-K filed Feb 25, 2026: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm
- 10-Q filed Aug 4, 2026: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000043/ew-20260630.htm
- DEF 14A filed Mar 26, 2026: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/